On July 13, 2022 NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company"), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, reported the Half-Year report on its liquidity contract with Gilbert Dupont (Press release, Nanobiotix, JUL 13, 2022, View Source [SID1234616656]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As of June 30, 2022, the following resources appeared on the liquidity account:

– Number of shares: 25,706
– Cash balance: € 60,051.07

During the 1st Half of 2022, a total of:

As of December 31, 2021, the following resources appeared on the liquidity account:

– Number of shares: 15,456
– Cash balance: € 97,415.97

Upon signing of the liquidity contract the following assets were made available:

– Number of shares: 0
– Cash balance: € 300,000.00

The implementation of this half-year report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.